Wells Fargo & Company Moon Lake Immunotherapeutics Transaction History
Wells Fargo & Company
- $433 Billion
- Q4 2024
A detailed history of Wells Fargo & Company transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, Wells Fargo & Company holds 325 shares of MLTX stock, worth $12,528. This represents 0.0% of its overall portfolio holdings.
Number of Shares
325
Previous 300
8.33%
Holding current value
$12,528
Previous $15,000
13.33%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding MLTX
# of Institutions
137Shares Held
58.1MCall Options Held
124KPut Options Held
96.9K-
Bvf Inc San Francisco, CA19.8MShares$761 Million39.28% of portfolio
-
Cormorant Asset Management, LP Boston, MA8.49MShares$327 Million35.64% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.34MShares$129 Million0.02% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.77MShares$107 Million2.15% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.19MShares$84.3 Million0.02% of portfolio
About MoonLake Immunotherapeutics
- Ticker MLTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,925,600
- Market Cap $1.42B
- Description
- MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...